Medical University of Vienna, Univ. Klinik für Innere Medizin III, Währinger Gürtel 18-20, A 1090 Vienna , Austria.
Expert Opin Drug Saf. 2011 Jul;10(4):529-44. doi: 10.1517/14740338.2011.555079. Epub 2011 Feb 23.
Approximately 170 million people are infected with HCV. The efficacy of treatment for chronic hepatitis C has increased markedly over the last 2 decades. Optimal patient management requires thorough knowledge of the adverse effect profiles of drugs used for this condition and strategies to mitigate these effects.
The efficacy, safety and tolerability data associated with IFN-based therapy, with particular attention given to the two licensed pegylated IFNs (peg-IFNs), are identified by focused searches of Medline. Recommendations for the management of adverse events are also given. Focused searches of PubMed are done using the terms peginterferon and chronic hepatitis C. The results of large randomized clinical trials are emphasized.
Patients receiving treatment with peg-IFN plus ribavirin for chronic hepatitis C must be monitored closely for adverse events. These events can be effectively managed to maximize patients' adherence and thus the chance of treatment success. Direct-acting antiviral agents are expected to be approved in the near future and will be used in select patients with a peg-IFN plus ribavirin 'backbone'.
约有 1.7 亿人感染 HCV。过去 20 年来，慢性丙型肝炎的治疗效果显著提高。要实现最佳的患者管理，需要全面了解治疗这种疾病所用药物的不良反应概况，并制定减轻这些影响的策略。
通过对 Medline 的重点搜索，确定了基于 IFN 的治疗的疗效、安全性和耐受性数据，特别关注两种已获许可的聚乙二醇化 IFN（peg-IFN）。还给出了管理不良反应的建议。通过使用术语 peginterferon 和慢性丙型肝炎，在 PubMed 上进行了重点搜索。强调了大型随机临床试验的结果。
接受 peg-IFN 联合利巴韦林治疗慢性丙型肝炎的患者必须密切监测不良反应。可以有效地管理这些事件，以最大限度地提高患者的依从性，从而提高治疗成功的机会。直接作用抗病毒药物预计将在不久的将来获得批准，并将在具有 peg-IFN 加利巴韦林“骨干”的特定患者中使用。
